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Abstract
Solitary fibrous tumors (SFTs) of the liver are rarely described; only 38 cases have been reported in literature, most
of which have shown benign clinical characteristics, and only 3 of these cases exhibited malignant variants. In this
study, we present a 24-year-old woman with a 1-month history of a rapidly enlarging abdominal mass and a CT
showing an exophytic heterogeneous liver mass with a firm parietal bone mass. The patient underwent a
transcatheter arterial chemoembolization (TACE) before operation, and an extended right hepatectomy and
craniectomy with a negative margin was performed under general anesthesia. The masses showed histological
features of oval spindle cells haphazardly arranged in the classic short-storiform or so-called patternless pattern of
solitary fibrous tumors. The tumor cells showed positive immunohistochemical reactions to CD34 and bcl-2. The
tumor recurred in the residual liver 2 months after operation, metastatic osteoblastic lesions in the thoracic and
lumbar vertebrae were identified 3 months after the operation, and lumbar vertebrae metastasis 7 months after
operation paralyzed the patient. The patient underwent percutaneous ethanol injection therapy (PEI) and
chemotherapy, but the patient died because of the uncontrolled tumor 16 months after the initial operation. To
our knowledge, this is the first case of malignant solitary fibrous liver tumors with skeletal metastasis.
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Introduction
Solitary fibrous tumors (SFTs) are a rare soft-tissue neo-
plasm that was initially described most commonly in the
pleural cavity[1]. In the past decade, SFTs have been
discovered at many body sites, including the liver
(mostly the right lobe), orbits, superior respiratory tract,
abdomen, breast and soft tissue [2-4]. SFTs are spindle
cell neoplasms. The histogenesis of SFT has been a mat-
ter of contention and still has not been definitively dis-
cerned, but a mesenchymal origin is favored over a
mesothelial origin[5].
More than 80% of SFTs are benign, asymptomatic and
slow-growing tumors, but malignant and symptomatic
forms, most often in the pleura, have been described
[6,7]. Clinical and radiological findings are not specific
and cannot exclude malignancy. Preoperative cytology
may be inconclusive or misleading. Notably, all SFTs
that recurred or metastasized after resection in some
larger series were ≥ 10 cm [8,9]. In addition, several
authors describe a histologically malignant component
with increased cellularity and mitoses in otherwise
benign-appearing SFTs, as a frequent occurrence in
tumors that recurred or metastasized [8-10]. The
recommended treatment of SFT is surgical resection.
Despite this treatment, SFTs can recur and metastasize
and have reported 10-year overall survival rates of 54-
89% after a complete surgical resection [11].
However, surgical experience with SFTs of the liver is
notably limited. In one series, 13.5% of 37 pleural SFTs
metastasized [12]. SFT is rarely located in the liver par-
enchyma and usually follows a benign course. Few case
reports in the literature describe a local recurrence of
liver SFT and even fewer describe metastases [12-16]. In
this study, we report a case of malignant liver SFT with
skeletal metastasis and discuss the clinical presentation,
previous diagnoses, radiological characteristics, histo-
pathological and immunohistiochemical features,
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surgical treatment, adjunctive therapy and prognosis of
SFTs with a review of the literature.
Case report
A 24-year-old, unmarried, nulliparous woman had pre-
sented one month earlier with upper right abdominal
discomfort, distention, and vague right quadrant pain.
The patient was a shop assistant for 4 years with no
known history of potential environmental hazardous
substances exposure. In addition, she was also a non-
smoker. Except for being a carrier of hepatitis B, she
had no relevant medical or family history. For the
further evaluation of her symptoms, she was referred to
the referral hospital, where a contrast enhanced compu-
ter tomography (CT) study revealed a 30-cm exophytic
heterogeneous mass in the right lobe of the liver (Figure
1). In a 2-D view, the lesion appeared as a hypodense
area without calcifications measuring 28 cm×18 cm. An
arterial-phase infusion of contrast showed peripheral
enhancements with thin linear areas of enhancement
(probably vessel-related) in the lesion. In the portal
phase, there was a dishomogeneous enhancement with
multiple hypodense areas. In the late phase, the lesion
showed a light enhancement (similar to normal liver tis-
sue) with multiple strong hypodense areas. There was
no presence of ascites, and the patient had been given
hepatinica. The patient was admitted to our hospital for
surgery.
On examination, abdominal distension was present.
Palpation revealed tenderness and a large, firm mass in
the right hypochondrium and epigastrium, and the liver
was 12 cm below the lower edge of the ribs. There was
no evidence of ascites, edema, hepatic failure, or cirrho-
sis stigmata. A firm mass of 4 cm×5 cm×3 cm was pre-
sent on the right parietal bone without any tenderness
(Figure 2). Laboratory tests, including routine biochem-
istry, liver function tests, urinalysis were normal, and
tumor markers, such as serum carbohydrate antigen
(CA)-125 was abnormal, whereas cancer antigen (CEA),
a-fetoprotein, and CA19-9 levels were in the normal
ranges. The patient’s cranial CT scan revealed a parietal
mass that was thought to be a metastatic tumor. On a
whole-body skeletal scan, increased activity was found
in the right parietal bone.
The patient underwent angiography and transcatheter
arterial chemoembolization (TACE, using diamminedi-
chloroplatinum 60 mg, 5-fluorodeoxyuridine 1000 mg,
Epirubicin 30 mg + 18-ml Lipiodol emulsifier) of the
tumor-supplying vessels a few days before operation
(Figure 3). A laparotomy was performed 8 days after
admission and revealed that the tumor had pushed the
colon to left and had adhered to the colon, stomach and
omenta. An extended right hepatectomy was performed,
and the postoperative course was uneventful. The gross
examination revealed a large tumor measuring 30 × 17
× 15 cm and weighing 3750 g that was a firm, whitish,
Figure 1 Enhanced CT scan before hepatectomy. A: Arterial phase image showing a large, heterogeneous mass of the liver with hypodense
areas, which had clear border between tumor and the normal liver. Lesion showed heterogeneous enhancement and the high density of tumor
blood vessels was seen in this region, lower density area to the central region as the center radial arrangement. Left hepatic vein was be
compressed by the tumour and turned out to be rigidity. B: Venous late phase images showing a large, solid mass of the liver. Large hypodense
tumor of the right hepatic lobe with an enhancement of the peripheral portion. The tumour was diffuse enhanced with a lager hypodense area
in the center thought to be necrosis.
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fibrotic nodule-encapsulated mass with necrosis (Figure
4). The resection margins were tumor-free. The tumor
was located in the liver parenchyma, not in relation to
the serosal surface. The cells were spindle-shaped tumor
cells that were highly cellular and pleomorphic with
areas of necrosis and a high mitotic index (> 10/hpf),
haphazardly arranged in the classic short-storiform or
so-called patternless pattern, and invading the surround-
ing liver tissue (Figure 5). The immunohistochemical
analysis was strong positive for CD34, Bcl-2 and Vimen-
tin. Ki-67 antigen staining was 3-5% positive. The tumor
cells were negative for other markers, such as CD117,
SM-actin, S-100, CD68, Myo-D1, CD99, Desmin, CD31,
Calretinin, Synaptophysin, Cytokeratin, and Keratin (Fig-
ure 6). A craniectomy was performed 13 days after the
extended right hepatectomy. The pathological examina-
tion showed skull base metastases from a malignant
solitary fibrous tumor of the liver.
A postoperative MRI examination in July 2010 demon-
strated that the postsurgical residual lesion was still large.
At follow-up one month later, the patient had severe back
and waist pain. An MRI identified metastatic osteoblastic
lesions of the thoracic and lumbar vertebrae (Figure 7).
The patient underwent four percutaneous ethanol-
injection therapies (PEIs) and was treated with four
rounds of chemotherapy that included adriamycin (40
mg on days 1-3), ifosfamide (3.0 g on days 1-4), and
mesna (0.6 g IV 0 h, 4 h, and 8 h after IFO). Adjunctive
radiation therapy was not administered. Despite the
treatment, the tumor relapsed rapidly and was markedly
enlarged. At follow-up seven months later, the patient
was paralyzed; the patient died 16 months after the
initial operation.
Discussion
Hepatic SFTs are unusual neoplasms, with 38 previous
cases worldwide being reported in the literature. SFTs
typically affect adults aged 54.6 years (16-83) with no
underlying predisposing factors. In a review article of 14
published cases, a strong female predilection was noted,
and the average follow-up period was 27 months
Figure 2 Metastatic tumor of the right parietal bone. A: CT scan
of the brain shows that the right parietal bone is ruined before the
craniectomy. B: CT scan of the brain after craniectomy. C: The
emission-computed tomography scan shows an abnormal
distribution of radioactivity in the right parietal bone area; the
sparse distribution of radioactivity was central; peripheral
distribution of radioactivity uptake before craniectomy.
Figure 3 CT scan after the treatment of TACE shows that there is almost no lipiodol deposits in the tumor area.
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[17,18]. Most of these cases showed benign clinical char-
acteristics, and only 3 cases had malignant variants. The
clinicopathological features of the malignant hepatic
SFT cases reported are summarized in Table 1. Three
well-described cases, including the present case, came
from one woman and two men with SFTs in the right
lobe of the liver, and these patients ranged in age from
25 to 70 years (mean: 49). Immunohistochemically, the
tumor cells showed strong vimentin immunostaining in
all three cases and were positive for CD34 in two cases
but negative for EMA and S-100 protein. The present
case seems to be the first case of a hepatic malignant
solitary fibrous tumor with skeletal metastases.
Clinically, hepatic SFTs cause symptoms only after
reaching a certain size, or when vital structures are
involved. SFTs are not known to grow invasively, and
the course of the disease following complete surgical
resection is usually benign. The patient may be asymp-
tomatic or have non-specific clinical manifestations,
including increased abdominal volume and circumfer-
ence and abdominal pain, distention, and discomfort, as
seen in our patient, or other symptoms, such as anor-
exia, nausea, vomiting and weight loss. Fever, hypoglyce-
mia, abnormal liver tests and biliary-duct compression
that leads to cholestasis and progressive jaundice are
less commonly seen [12,13,16,19]. Laboratory results are
usually normal; however, a few patients have had
deranged liver function tests or elevated serum levels of
a-fetoprotein [15,19,20]. Our patient had a high level of
serum CA125.
The radiological findings of SFTs are unspecific and
cannot distinguish between benign and malignant
tumors. The diagnosis should be suspected if imaging
reveals a solitary, highly vascular, well circumscribed,
encapsulated mass that shows heterogeneous enhance-
ment (due to the varied density of the collagen compo-
nent) in CT and MRI images, especially if the
enhancement is hypointense on the T2-weighted MRI
and shows progressive enhancement in the delayed
phase [20]. Most benign or malignant liver tumors,
including hemangiomas, hepatic adenomas, focal nodu-
lar hyperplasia, hepatocellular carcinomas, fibrolamellar
hepatocellular carcinomas and peripheral mass-forming
cholangiocarcinomas, are predominantly hyperintense
on the T2-weighted images, and some have a delayed,
persistent enhancement [21]. The imaging features of
benign and malignant solitary fibrous liver tumors
appear to overlap. DWI can differentiate solitary fibrous
tumors from malignant liver tumors. A whole-body
fluorodeoxyglucose positron emission tomography (PET)
showed that the mass had low metabolic activity and
was probably benign [13,22].
Several authors believe that fine-needle aspiration also
helps to establish a diagnosis, if the tissue sample is ade-
quate and the fine-needle aspiration can be analyzed for
immunomarkers; there has been one successful case
report of this practice [23]. Other authors regard fine-
needle biopsy to be inaccurate and do not recommend
this practice. Large solid lesions of the liver (irrespective
of the diagnosis), if deemed resectable at the pre- and
intraoperative assessment, should be excised and sent
for histological examination. Specimens obtained from a
fine-needle biopsy only represent a small area of the
tumor and may be misleading when entrapped prolifer-
ating bile ducts are mistaken for an adenocarcinoma, as
in the present case. Alternatively, malignant foci may be
missed, which would give a falsely reassuring result.
Figure 4 The resected specimen, which measured 30 × 17 × 15
cm after an extended right hepatectomy.
Figure 5 Microscopic appearance. (A) The mitosis of the nucleus.
(B) Heteromorphism of the tumor. (C) and (D) Juncture of the
tumor.
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Figure 6 Immunohistochemical features. (A) Diffuse and strong CD34 immunopositivity. (B) Negative CD68 antigen staining. (C) Positive bcl-2
antigen staining. (D) Negative CD99 antigen staining. (E). Diffusely negative S-100 staining. (F) Negative smooth-muscle actin.(G) 3-5% positive Ki-
67 antigen staining. (H) Negative cytokeratin antigen staining. (I) Positive vimentin antigen staining. (J) Negative synaptophysin antigen staining.
(K) Negative calretinin. (L) Negative Desmin antigen staining. (M) Negative CD31 antigen staining.
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Moreover, if the tumor is malignant, a percutaneous
biopsy may seed tumor cells along the biopsy tract
[7,22].
The tumor may be found on either the right or left
side of the liver. The average tumor weight, where avail-
able, was 3,184 g and ranged from 1,850 g to 4,500 g.
The mean of the largest diameter was 17.8 cm (2-32
cm)[18]. Paula Novais [24] presented a case of a large
solitary hepatic fibrous tumor that was unresectable at
first. Two years later, another attempt at surgical
resction was made, but a life-threatening surgical com-
plication occurred during the postoperative course.
Unresectable, rare, non-hepatocellular or bile duct
tumors that arise within the hepatic parenchyma are a
formal indication for liver transplantation; therefore,
liver transplantation can be considered for non-resect-
able SFTs. Because the patient was stable for 4 years,
the author questioned such aggressive treatments in
asymptomatic patients, due to the natural history of this
tumor, which is not well known, and the risk of other
complications.
In the present case, the liver SFT diagnosis was based
on the association of characteristic histological and
immunohistochemical features (i.e., high cellular prolif-
eration of spindle cells arranged in a storiform pattern)
with the immunohistochemical staining profile of CD34
(+), Bcl-2 (+) and SM-actin (-). These characteristics dif-
ferentiate SFTs from other liver tumors, such as primary
Figure 7 Magnetic resonance imaging shows metastatic osteoblastic lesions of the thoracic and lumbar vertebrae 3 months after
operation.
Table 1 Clinicopathological features of the reported malignant cases of liver solitary fibrous tumors
No Reference Year Age/
sex











2007 70/M Excision 27 × 24 × 12 Right Vimentin+,
CD34+, Bcl2+, CD99+
spindle-cell fibrosarcoma: highly cellular and
pleomorphic, with areas of necrosis and a






2010 54/M Excision 17 × 12 × 8 Right Vimentin+, CD34+,
desmin+, actin+
Tumor cells were polymorphic: small and
round, spindle-shaped, voluminous with
acidophilic cytoplasm, or with polymorphous
nuclei.
9 years
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hepatocellular carcinomas (CD34-negative), leiomyomas
(smooth-muscle actin-positive and CD34-negative) and
mesotheliomas (vimentin-positive, CD34-positive, cyto-
keratin-positive) [25]. However, the CD34 antibody is
not specific for SFT diagnosis and can be positive in
angiosarcomas and gastrointestinal stromal tumors.
A hepatic SFT is often a benign neoplasm that has a
good prognosis after surgery without recurrence. Most
authors believe that postoperative adjuvant chemother-
apy or radiotherapy should be reserved for incomplete
resections and/or pathological features of malignancy
[25,26]. Currently, the combination of doxorubicin and
ifosfamide is the standard systemic chemotherapy regi-
men for many subtypes of soft-tissue sarcomas. Gemci-
tabine with docetaxel has also emerged as a good
therapeutic choice for these patients. Although cases of
SFT that respond to these chemotherapeutic agents
have been reported sporadically, no systematic review or
clinical trial has identified an effective systemic regimen
for an unresectable SFT to date[11]. However, it has
been proven that standard chemotherapy regimens may
only have limited efficacy in SFT. The combination of
temozolomide and bevacizumab had a remarkably high
rate of overall response and a favorable duration of dis-
ease control; temozolomide/bevacizumab is a promising
therapeutic regimen that warrants further investigation.
When complete resection is impossible or when there
is recurrence, radiotherapy can be used, but a negative
surgical margin does not mean that radiotherapy is
unnecessary. Postoperative radiotherapy may theoreti-
cally reduce the risk of local recurrence; therefore, post-
operative radiotherapy should be used as an adjunctive
therapy in all patients [27]. In our case, we also used
TACE for arterial embolization several days before
operation. TACE is an option to generate tumor hypo-
trophy for a better resection and reduced hemorrhagic
risk. Almost all reports agree that a complete surgical
resection with tumor-free margins remains the corner-
stone of treatment because of the reported 10-year over-
all survival rates of 54-89% [11]. The current case had
widespread skeletal metastases; therefore, we used che-
motherapy (adriamycin and ifosfamide), but this sys-
temic regimen seemed to be inadequate. We believe
that this report will contribute to understanding the nat-
ural history of liver SFTs.
SFTs of the liver are a rare neoplasm that cannot be
definitely diagnosed by characteristic histological and
immunohistochemical properties. A complete surgical
resection with tumor-free margins is the best choice for
treatment. Postoperative adjuvant chemotherapy or
radiotherapy should be used in malignant SFTs; how-
ever, the use of these therapies in benign SFTs is still
controversial.
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